Personalized therapy study for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests if matching treatments to your tumor's genetic markers can help slow down metastatic colorectal cancer. You'll get a biopsy and blood draw to guide your therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with metastatic colorectal cancer
- You are well enough to be up and about (ECOG score 0, 1, or 2)
- Your cancer can be measured on scans
- You are about to start standard cancer therapy
- You need a tumor biopsy or surgery as part of your regular care
- You agree to give a blood sample for genetic testing and have your first scan at Mayo Clinic
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if checking your blood for tumor DNA after two rounds of chemotherapy can help doctors decide if they can safely lower the dose or switch your treatment. It's for people with advanced colorectal cancer that started on the left side or in the rectum.
This trial studies personalized (precision) treatment decisions for people with advanced or recurrent colorectal cancer. It aims to improve outcomes while carefully monitoring safety and how well the plan fits each participant.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This trial tests whether using a personalized approach (matching your tumor's genetic profile to a targeted drug) can help people with advanced solid cancers live longer. It is for people whose cancer is not responding to standard treatments and who have a genetic change that can be targeted by an FDA-approved drug not usually used for their cancer type.
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
Hear when a new Metastatic Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.